Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470476 | 0.91 | MAPT (0.49) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL458661 | 0.88 | HTR6 (0.45) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27913478 | 0.84 | MAPT (0.52) | MAPTSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL12272881 | 0.81 | ATR (0.41) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27913906 | 0.81 | MAPT (0.39) | MAPTSMN1; SMN2CYP2C19ALDH1A1KMT2A | |
| SCHEMBL24379384 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2CYP2C19ALDH1A1KMT2A | |
| SCHEMBL18300991 | 0.76 | MAPT (0.52) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25330719 | 0.76 | MAPT (0.46) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30195159 | 0.76 | MAPT (0.50) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL457220 | 0.76 | MAPT (0.52) | MAPTSMN1; SMN2CYP2C19ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103201268-B | As the novel piperazine analogue of wide spectrum influenza virus medicine | BRISTOL-MYERS SQUIBB CO. (US) | 2015-08-12 | — | — | CN | disclosed |
| EP-2614052-B1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-31 | — | — | EP | disclosed |
| CN-103201268-A | Novel piperazine analogs as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | MAPT 4757/4885SMN1; SMN2 4496/4885CYP1A2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.